sTCCC3dgSLEDAIC4diC3bsystemic lupus erythematosuslupus nephritisSLELupus nephritisConclusionsLund
…reflection of lupus activity than conventional C3 and C4 levels.sTCC were particularly informative for both active SLE and nephritis…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 61–120 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
Upadacitinib39NT-proBNP38Nintedanib38Tacrolimus38Levobupivacaine38Warfarin37Mycophenolate37Durvalumab36IVIG36PrEP35Ustekinumab35Levetiracetam34Alcohol34MMF33Azithromycin33Acetaminophen33Dupilumab32Gemcitabine32Steroids32Glucagon-like peptide-1 receptor agonists32Ursodeoxycholic Acid32Linezolid31Ticagrelor30Ezetimibe30Epinephrine30Furosemide30Amoxicillin30Remifentanil30Apixaban30Doxorubicin29Colchicine28Oxycodone28UDCA28ICS28Antidepressants28Atorvastatin27Trastuzumab27Tranexamic Acid27meropenem27Rivaroxaban27Beta-blockers27Metronidazole27Aflibercept26HCQ26Capecitabine26Gabapentin26Corticosteroid26Clonidine26Heparin26Medication26GLP-1RA25Methadone25IL-225Onyx25Ocrelizumab24Amiodarone24Local anesthetic24sufentanil24medications24GLP-1RAs23
Articles mentioning drugs
10,506 articles · page 68 of 876HydroxychloroquineMethylprednisoloneBelimumabAzathioprineRifampicinIVIgEthambutol hydrochlorideIsoniasidSystemic Lupus ErythematosusAntiphospholipid syndrome+2 more
…vity, Lupus nephritis. She was treated with Methylprednisolone, Hydroxychloroquine, Azathioprine, one infusion of Belimumab. After 18 month evolut…
rituximabmycophenolate mofetilGCHCQanifrolumabMMFSjögren’s syndromeSLESystemic Lupus Erythematosus
…d HCQ 400 mg/day. In August 2025, due to inadequate efficacy of rituximab (3 g), intolerance to MMF, and limitations on IS (due to leukop…
anifrolumabapixabanPrednisonewarfarinRituximabmethylprednisoloneSystemic Lupus ErythematousSLEACLECorticosteroid therapy
…thematous (SLE). We report a case of recurrent ALP treated with anifrolumab.Methods A 47-year-old man presented in August 2022 with progres…
rituximabhydroxychloroquineleflunomideMTXsulfasalazinetocilizumabmethylprednisoloneupadacitinibRhupus
… refractory to multiple therapies, highlighting the response to rituximab. Prior reports support the benefit of rituximab in SLE-associat…
92.9%
GCglucocorticoidsSLELupus Clinic
…and suggest that formal remission does not always coincide with GC withdrawal. Personalized management remains essential to optimi…
BelimumabBelimumabConclusionsMycophenolate MofetiltacrolimusazathioprineSLECork University Hospital
…l (66.7%), azathioprine (11%) and tacrolimus (11%)]. 2 received Belimumab monotherapy.Baseline combined SLEDAI was 10.2±3.9 (range 4-16),…
BelimumabBELSLEGSK Study 116543
…Objectives Belimumab (BEL) is a B-cell modulator targeting the central immunopathoge…
OBZSLEDAI-2KRTXRTX-refractoryRTX-RTXlupus nephritisIstanbul University-CerrahpasaSLE
… this small real-world cohort of RTX-refractory/intolerant SLE, OBZ yielded promising responses, including in lupus nephritis, with…
belimumabrituximabprednisonehydroxychloroquineSLE
…endent clinical trials: BEAT-lupus and CALIBRATE both comparing belimumab after rituximab vs. rituximab. We further evaluated its potenti…
hydroxychloroquinePDNprednisoloneSLECoimbra’s Hospital
…an age 31 years; median disease duration 9 years), 94% received hydroxychloroquine and 70% received immunosuppressants. Of those tapering PDN (n=7…
dapirolizumab pegolDZPprednisonePBOSLELupusNCT04294667
… outcomes, from the phase 3 PHOENYCS GO trial ( NCT04294667) of dapirolizumab pegol (DZP).DZP is a novel CD40L inhibitor with broad modulatory effe…